Literature DB >> 19056598

Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states.

Pablo Perez-Martinez1, Dolores Corella, Jian Shen, Donna K Arnett, Nikos Yiannakouris, E Syong Tai, Marju Orho-Melander, Katherine L Tucker, Michael Tsai, Robert J Straka, Michael Province, Chew Suok Kai, Francisco Perez-Jimenez, Chao-Qiang Lai, Jose Lopez-Miranda, Marisa Guillen, Laurence D Parnell, Ingrid Borecki, Sekar Kathiresan, Jose M Ordovas.   

Abstract

BACKGROUND: Hypertriglyceridemia is a risk factor for cardiovascular disease. Variation in the apolipoprotein A5 (APOA5) and glucokinase regulatory protein (GCKR) genes has been associated with fasting plasma triacylglycerol.
OBJECTIVE: We investigated the combined effects of the GCKR rs780094C-->T, APOA5 -1131T-->C, and APOA5 56C-->G single nucleotide polymorphisms (SNPs) on fasting triacylglycerol in several independent populations and the response to a high-fat meal and fenofibrate interventions.
DESIGN: We used a cross-sectional design to investigate the association with fasting triacylglycerol in 8 populations from America, Asia, and Europe (n = 7,730 men and women) and 2 intervention studies in US whites (n = 1,061) to examine postprandial triacylglycerol after a high-fat meal and the response to fenofibrate. We defined 3 combined genotype groups: 1) protective (homozygous for the wild-type allele for all 3 SNPs); 2) intermediate (any mixed genotype not included in groups 1 and 3); and 3) risk (carriers of the variant alleles at both genes).
RESULTS: Subjects within the risk group had significantly higher fasting triacylglycerol and a higher prevalence of hypertriglyceridemia than did subjects in the protective group across all populations. Moreover, subjects in the risk group had a greater postprandial triacylglycerol response to a high-fat meal and greater fenofibrate-induced reduction of fasting triacylglycerol than did the other groups, especially among persons with hypertriglyceridemia. Subjects with the intermediate genotype had intermediate values (P for trend <0.001).
CONCLUSIONS: SNPs in GCKR and APOA5 have an additive effect on both fasting and postprandial triacylglycerol and contribute to the interindividual variability in response to fenofibrate treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19056598      PMCID: PMC2647710          DOI: 10.3945/ajcn.2008.26363

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  32 in total

Review 1.  Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy.

Authors:  James D Otvos
Journal:  Clin Lab       Date:  2002       Impact factor: 1.138

2.  Replication validity of genetic association studies.

Authors:  J P Ioannidis; E E Ntzani; T A Trikalinos; D G Contopoulos-Ioannidis
Journal:  Nat Genet       Date:  2001-11       Impact factor: 38.330

3.  Analysis of serial measurements in medical research.

Authors:  J N Matthews; D G Altman; M J Campbell; P Royston
Journal:  BMJ       Date:  1990-01-27

4.  Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein.

Authors:  E D Slosberg; U J Desai; B Fanelli; I St Denny; S Connelly; M Kaleko; B R Boettcher; S L Caplan
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

5.  Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.

Authors:  Diane Brisson; Karine Ledoux; Yohan Bossé; Julie St-Pierre; Pierre Julien; Patrice Perron; Thomas J Hudson; Marie-Claude Vohl; Daniel Gaudet
Journal:  Pharmacogenetics       Date:  2002-06

Review 6.  Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice.

Authors:  Len A Pennacchio; Edward M Rubin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-12-26       Impact factor: 8.311

7.  Genetic variation at the perilipin (PLIN) locus is associated with obesity-related phenotypes in White women.

Authors:  L Qi; D Corella; J V Sorlí; O Portolés; H Shen; O Coltell; D Godoy; A S Greenberg; J M Ordovas
Journal:  Clin Genet       Date:  2004-10       Impact factor: 4.438

8.  Comparison of ultracentrifugation and nuclear magnetic resonance spectroscopy in the quantification of triglyceride-rich lipoproteins after an oral fat load.

Authors:  Michael Y Tsai; Angeliki Georgopoulos; James D Otvos; Jose M Ordovas; Naomi Q Hanson; James M Peacock; Donna K Arnett
Journal:  Clin Chem       Date:  2004-05-13       Impact factor: 8.327

Review 9.  Pharmacogenomics and drug response in cardiovascular disorders.

Authors:  G Siest; E Jeannesson; H Berrahmoune; S Maumus; J-B Marteau; S Mohr; S Visvikis
Journal:  Pharmacogenomics       Date:  2004-10       Impact factor: 2.533

10.  Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.

Authors:  J R Patsch; G Miesenböck; T Hopferwieser; V Mühlberger; E Knapp; J K Dunn; A M Gotto; W Patsch
Journal:  Arterioscler Thromb       Date:  1992-11
View more
  20 in total

1.  Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.

Authors:  Ariel Brautbar; Daniel Covarrubias; John Belmont; Fremiet Lara-Garduno; Salim S Virani; Peter H Jones; Suzanne M Leal; Christie M Ballantyne
Journal:  Atherosclerosis       Date:  2011-08-22       Impact factor: 5.162

2.  APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population.

Authors:  Carmen Sánchez-Moreno; Jose M Ordovás; Caren E Smith; Juan C Baraza; Yu-Chi Lee; Marta Garaulet
Journal:  J Nutr       Date:  2011-01-05       Impact factor: 4.798

3.  Fibrate pharmacogenomics: expanding past the genome.

Authors:  John S House; Alison A Motsinger-Reif
Journal:  Pharmacogenomics       Date:  2020-03-17       Impact factor: 2.533

Review 4.  Fatty acid interactions with genetic polymorphisms for cardiovascular disease.

Authors:  Caren E Smith; José M Ordovás
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-03       Impact factor: 4.294

5.  Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD.

Authors:  L Maria Belalcazar; George D Papandonatos; Bahar Erar; Inga Peter; Hadeel Alkofide; Ashok Balasubramanyam; Ariel Brautbar; Steven E Kahn; William C Knowler; Christie M Ballantyne; Jeanne M McCaffery; Gordon S Huggins
Journal:  Circ Cardiovasc Genet       Date:  2015-11-17

6.  Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study.

Authors:  María-José Ariza; Miguel-Angel Sánchez-Chaparro; Francisco-Javier Barón; Ana-María Hornos; Eva Calvo-Bonacho; José Rioja; Pedro Valdivielso; José-Antonio Gelpi; Pedro González-Santos
Journal:  BMC Med Genet       Date:  2010-04-29       Impact factor: 2.103

7.  Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: the ARIC Study.

Authors:  Mark Bi; Wen Hong Linda Kao; Eric Boerwinkle; Ron C Hoogeveen; Laura J Rasmussen-Torvik; Brad C Astor; Kari E North; Josef Coresh; Anna Köttgen
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

8.  Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients.

Authors:  Pablo Perez-Martinez; Juan F Alcala-Diaz; Edmon K Kabagambe; Antonio Garcia-Rios; Michael Y Tsai; Javier Delgado-Lista; Genovefa Kolovou; Robert J Straka; Francisco Gomez-Delgado; Paul N Hopkins; Carmen Marin; Ingrid Borecki; Elena M Yubero-Serrano; James E Hixson; Antonio Camargo; Michael A Province; Javier Lopez-Moreno; Fernando Rodriguez-Cantalejo; Francisco J Tinahones; Dimitri P Mikhailidis; Francisco Perez-Jimenez; Donna K Arnett; Jose M Ordovas; Jose Lopez-Miranda
Journal:  J Clin Lipidol       Date:  2016-06-01       Impact factor: 4.766

9.  Glucokinase regulatory protein gene polymorphism affects postprandial lipemic response in a dietary intervention study.

Authors:  Haiqing Shen; Toni I Pollin; Coleen M Damcott; John C McLenithan; Braxton D Mitchell; Alan R Shuldiner
Journal:  Hum Genet       Date:  2009-06-13       Impact factor: 4.132

10.  What lies behind serum urate concentration? Insights from genetic and genomic studies.

Authors:  Kimiyoshi Ichida
Journal:  Genome Med       Date:  2009-12-29       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.